Es werden RNA-Moleküle (SEQ ID Nos. 1 bis 6) bereitgestellt, die mit der Virulenz und/oder dem Wachstum von Streptococcus spec. in einem Patienten assoziiert sind. Diese RNA-Moleküle mit einer Länge von wenigstens 10 Nukleotiden sowie die reversen, komplementären oder revers-komplementären Sequenzen (SEQ ID Nos. 7 bis 24) oder Sequenzen, die wenigstens 90 % Identität mit diesen Sequenzen zeigen, werden als Zielmoleküle für die Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Infektionserkrankungen, an denen Streptococcus spec. beteiligt ist, vorgeschlagen.RNA-molecule having a sequence with a length of at least 10 nucleotides, which consist of one of the sequences of SEQ ID NO: 1 (a 143 base pair sequence fully defined in the specification), SEQ ID NO: 2 (a 228 base pair sequence fully defined in the specification), SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 or reverse, complementary or reverse-complementary sequences according to SEQ ID NO: 23 (a 227 base pair sequence fully defined in the specification), SEQ ID NO: 24 (a 242 base pair sequence fully defined in the specification), and SEQ ID NO: 7-22, is new. RNA-molecule having a sequence with a length of at least 10 nucleotides, which consist of one of the sequences of SEQ ID NO: 1 (a 143 base pair sequence fully defined in the specification), SEQ ID NO: 2 (a 228 base pair sequence fully defined in the specification), SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO: 6 or reverse, complementary or reverse-complementary sequences according to SEQ ID NO: 23 (a 227 base pair sequence fully defined in the specification), SEQ ID NO: 24 (a 242 base pair sequence fully defined in the specification) and SEQ ID NO: 7-22, where the sequences of SEQ ID NO: 7-22 and of SEQ ID NO: 3-6 are not defined, the RNA molecule has a virulence-associated function in Streptococcus sp. and/or an essential function for the growth of Streptococcus sp., is new. Independent claims are included for: (
